A majority of Australian GPs support medicinal cannabis being available on prescription, with their preferred "access model" involving trained GPs prescribing independently of specialists.
In 2013, UCSF Benioff Children’s Hospital San Francisco became the first site to administer the drug in a child, and as of this week, the FDA has approved its use in two rare and devastating forms of epilepsy.
The lab will run full-service testing for cannabinoid profiles, terpenes, pesticides, heavy metals, biological screening, and residual solvents, testing for 10+ cannabinoids and 40+ terpenes.
While medical marijuana supporters may cite the FDA approval of Epidiolex as evidence of the benefits of marijuana, it is not an endorsement of any CBD or cannabis product.
A patent has been filed for the use of cannabis therapies for the manipulation of ion channels in sensory neurons that contribute to chronic pain, peripheral neuropathy, urinary cystitis, asthma, and specific types of hearing loss.
The designation has been given to Revive Therapeutics for the use of CBD in treating autoimmune hepatitis.
As the California cannabis industry evolves and state-mandated laboratory standards of operation prove vital, both clients and consumers will now have assurance that the results will be accurate and reliable.
Epidiolex contains cannabidiol (CBD) and is the first FDA-approved drug that contains a purified drug substance derived from marijuana.